论文部分内容阅读
目的:探讨康莱特注射液联合放化疗对中晚期宫颈癌患者的疗效及对放化疗引起的毒副反应的影响。方法:选取2009年6月—2012年3月间笔者所在医院收治的经病理组织学确诊的62例局部晚期宫颈鳞癌患者,随机平均分成实验组(n=31)和对照组(n=31),分别接受康莱特注射液+放化疗联用和单纯放化疗的治疗,考察两组受试者的临床有效率、生活质量及毒副反应。结果:实验组和对照组受试者的总有效率分别为93.6%和83.9%,无显著差异(P>0.05);生活质量稳定和改善的比率分别为93.5%和71.0%,有显著差异(P<0.05);实验组受试者的主要毒副反应发生率明显低于对照组(P<0.05)。结论:康莱特注射液联合放化疗能有效用于中晚期宫颈癌患者的治疗,并显著提高患者生活质量,明显减轻放化疗所致不良反应。
Objective: To investigate the effect of Kanglaite injection combined with chemoradiotherapy on patients with advanced cervical cancer and its effects on the side effects caused by radiotherapy and chemotherapy. Methods: Totally 62 patients with locally advanced cervical squamous cell carcinoma diagnosed by our hospital from June 2009 to March 2012 were randomly divided into experimental group (n = 31) and control group (n = 31) ) Were treated with Kanglaite injection combined with radiotherapy and chemotherapy and radiotherapy and chemotherapy alone. The clinical efficacy, quality of life and toxicity of the two groups were investigated. Results: The total effective rates of the experimental group and the control group were 93.6% and 83.9%, respectively, with no significant difference (P> 0.05). The rates of stable and improved quality of life were 93.5% and 71.0%, respectively P <0.05). The incidence of major toxicities in the experimental group was significantly lower than that in the control group (P <0.05). Conclusions: Kanglaite Injection combined with radiochemotherapy can be effectively used in the treatment of advanced cervical cancer patients, and significantly improve the quality of life of patients, significantly reduce the adverse reactions caused by radiotherapy and chemotherapy.